The Global Biologics CDMO Market is expected to witness a growth rate of 14-16% in the next five years. Growing ...

After the launch of Ustekinumab, a biosimilar of Stelara, in the United States and Europe, Biocon Biologics’ biosimilar drug ...

Companies remain exposed to heightened risks between the world’s largest markets and are now cautious of the stability of ...

The US FDA has approved Incyte’s Zynyz (retifanlimab-dlwr) in conjunction with carboplatin and paclitaxel (platinum-based ...

The initiatives reflect the latest measures from federal agencies to reduce and ultimately replace animal testing in drug development and ...

The potential of monoclonal antibodies (mAbs ... AI/ML models last year. AI-biologics vs. AI-small molecule discovery spaces Compared to the small molecule AI drug discovery ecosystem, this ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous ...

The Large Molecule Bioanalytical Technologies Market is expected to grow from USD 9.29 Billion in 2024 to USD 16.76 Billion ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody ... companies such as Innovent Biologics, RemeGen, or KeyMed ...

The lyophilized injectable market is poised for growth due to increasing demand for biologics and specialty drugs, R&D activities, and global collabo ...